These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27424282)

  • 21. Who should donate blood? Policy decisions on donor deferral criteria should protect recipients and be fair to donors.
    Brailsford SR; Kelly D; Kohli H; Slowther A; Watkins NA;
    Transfus Med; 2015 Aug; 25(4):234-8. PubMed ID: 26190553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
    Martin M; Trouvin JH
    Transfus Clin Biol; 2013 Sep; 20(4):398-404. PubMed ID: 23910008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products. PLUS.
    Mahony BO; Turner A
    Vox Sang; 2010 Apr; 98(3 Pt 2):447-50. PubMed ID: 20158697
    [No Abstract]   [Full Text] [Related]  

  • 24. Compensation for Blood Plasma Donation as a Distinctive Ethical Hazard: Reformulating the Commodification Objection.
    Walsh A
    HEC Forum; 2015 Dec; 27(4):401-16. PubMed ID: 26100662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mode of preparation of labile blood products--available products].
    Lapierre V; Hervé P
    Presse Med; 1999 Jul 3-10; 28(24):1314-20. PubMed ID: 10442066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ethics and transfusion--seminar report].
    Hervé C; Tissot JD; Bouësseau MC; Pottier R; Monsellier M; Garraud O; Hermine O; Sannié T; Cazenave JP; Cabaud JJ; Lefrère JJ
    Transfus Clin Biol; 2014 May; 21(2):66-76. PubMed ID: 24814818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood donors on medication. Are deferral periods necessary?
    Stichtenoth DO; Deicher HR; Frölich JC
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):433-40. PubMed ID: 11699606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Techniques of preparation and indications of labile blood products].
    Clément S
    Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients.
    Klausen SS; Hervig T; Seghatchian J; Reikvam H
    Transfus Apher Sci; 2014 Oct; 51(2):97-102. PubMed ID: 25242310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ethics of blood management.
    Sazama K
    Vox Sang; 2007 Feb; 92(2):95-102. PubMed ID: 17298570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Availability of blood components and plasma derived medicines in Iran.
    Cheraghali AM
    Transfus Apher Sci; 2007 Aug; 37(1):3-7. PubMed ID: 17707696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
    Lee JY; Hunt P
    J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Autotransfusion and concentrates or donor blood and fresh plasma? Legal pitfalls in the medical decision making paths (Part 1 of two)].
    Schlund GH
    Fortschr Med; 1993 Jun; 111(17):45-8. PubMed ID: 8349275
    [No Abstract]   [Full Text] [Related]  

  • 36. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components.
    Gajic O; Yilmaz M; Iscimen R; Kor DJ; Winters JL; Moore SB; Afessa B
    Crit Care Med; 2007 Jul; 35(7):1645-8. PubMed ID: 17522583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Blood donation: Representations and issues associated with blood product collection].
    Loquier B; Zegierman A; Pelletier B
    Transfus Clin Biol; 2015 Aug; 22(3):127-31. PubMed ID: 26112917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ethics of blood management.
    Weiskopf RB
    Vox Sang; 2007 Jul; 93(1):91. PubMed ID: 17547572
    [No Abstract]   [Full Text] [Related]  

  • 39. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
    Cheraghali AM; Aboofazeli R
    Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.